Targeting Microglia for Therapy of Parkinson's Disease by Using Biomimetic Ultrasmall Nanoparticles
Hanghang Liu1, Yaobao Han1, Tingting Wang1
1Center for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Suzhou 215123, P. R. China.
Abstract:
Microglia as an important type of innate immune cell in the brain have been considered as an effective therapeutic target for the treatment of central nervous degenerative diseases. Herein, we report cell membrane coated novel biomimetic Cu2-Se-PVP-Qe nanoparticles (denoted as CSPQ@CM nanoparticles, where PVP is poly(vinylpyrrolidone), Qe is quercetin, and CM is the cell membrane of neuron cells) for effectively targeting and modulating microglia to treat Parkinson's disease (PD). The CSPQ nanoparticles exhibit multienzyme activities and could effectively scavenge the reactive oxygen species and promote the polarization of microglia into the anti-inflammatory M2-like phenotype to relieve neuroinflammation. We reveal that biomimetic CSPQ@CM nanoparticles targeted microglia through the specific interactions between the membrane surface vascular cells adhering to molecule-1 and α4β1 integrin expressed by microglia. They could significantly improve the symptoms of PD mice to result in an excellent therapeutic efficacy, as evidenced by the recovery of their dopamine level in cerebrospinal fluid, tyrosine hydroxylase, and ionized calcium binding adapter protein 1 to normal levels. Our work demonstrates the great potential of these robust biomimetic nanoparticles in the targeted treatment of PD and other central nervous degenerative diseases.
Insights
Novel biomimetic nanoparticles effectively target and modulate brain microglia, offering a promising new treatment for Parkinson's disease (PD) and other neurodegenerative disorders by reducing neuroinflammation.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Pharmacology
Background:
- Microglia, key innate immune cells in the brain, are crucial therapeutic targets for neurodegenerative diseases.
- Parkinson's disease (PD) involves neuroinflammation, making microglia modulation a potential treatment strategy.
Purpose of the Study:
- To develop and evaluate novel biomimetic nanoparticles for targeted microglia modulation in Parkinson's disease treatment.
- To investigate the therapeutic efficacy of these nanoparticles in alleviating neuroinflammation and improving PD symptoms.
Main Methods:
- Fabrication of cell membrane-coated copper selenide-polyvinylpyrrolidone-quercetin nanoparticles (CSPQ@CM).
- Assessment of nanoparticle multienzyme activities, reactive oxygen species scavenging, and microglia polarization.
- Evaluation of nanoparticle targeting mechanisms via specific molecular interactions with microglia.
- In vivo testing in Parkinson's disease mouse models to assess therapeutic effects.
Main Results:
- CSPQ@CM nanoparticles demonstrated multienzyme activities and effectively scavenged reactive oxygen species.
- Nanoparticles promoted microglia polarization towards an anti-inflammatory M2-like phenotype, reducing neuroinflammation.
- Specific targeting of microglia was confirmed through interactions with expressed integrins.
- Significant improvement in PD mouse symptoms was observed, with recovery of dopamine levels and key protein expressions.
Conclusions:
- Biomimetic CSPQ@CM nanoparticles show great potential for targeted treatment of Parkinson's disease.
- These nanoparticles offer a promising therapeutic strategy for central nervous system degenerative diseases by modulating microglia.
- The study highlights the robustness and efficacy of these novel biomimetic nanoparticles in a preclinical setting.
